Maze’s new kidney pill MZE829 cut harmful protein in urine by 35.6% in its Phase 2 trial — including patients with diabetes. Stock still fell 30% as analysts say “don’t compare it to Vertex” but remain very bullish.
BofA reaffirms Buy on Vera Therapeutics; Vertex’s povetacicept Phase 3 interim results in IgAN meet expectations but pose no major competitive threat.
Vertex Pharmaceuticals' povetacicept succeeds in Phase 3 RAINIER trial for IgA nephropathy with 52% proteinuria reduction. Positive safety data and FDA submission planned soon.
CRISPR Therapeutics stock surges 6% amid fresh speculation that Vertex Pharmaceuticals may pursue an acquisition.
Morgan Stanley upgrades Vertex Pharmaceuticals on promising kidney pipeline progress and downgrades Regeneron due to balanced risk/reward and valuation concerns.
Vertex Pharmaceuticals' stock fell after its pain drug VX-993 failed a trial. Despite this, Q2 earnings exceeded estimates, driven by cystic fibrosis drugs. Journavx also faces FDA limitations.
